FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

BACKGROUND: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer. AIM: To investigate th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:World J Gastrointest Oncol
Glavni autori: Vienot, Angélique, Chevalier, Hortense, Bolognini, Clément, Gherga, Elisabeta, Klajer, Elodie, Meurisse, Aurélia, Jary, Marine, Kim, Stefano, d’Engremont, Christelle, Nguyen, Thierry, Calcagno, Fabien, Almotlak, Hamadi, Fein, Francine, Nasri, Meher, Abdeljaoued, Syrine, Turpin, Anthony, Borg, Christophe, Vernerey, Dewi
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2020
Teme:
Observational Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7081111/
https://ncbi.nlm.nih.gov/pubmed/32206183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v12.i3.332
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items